![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZNF569 |
Gene summary for ZNF569 |
![]() |
Gene information | Species | Human | Gene symbol | ZNF569 | Gene ID | 148266 |
Gene name | zinc finger protein 569 | |
Gene Alias | ZAP1 | |
Cytomap | 19q13.12 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q5MCW4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
148266 | ZNF569 | ATC13 | Human | Thyroid | ATC | 3.35e-36 | 6.14e-01 | 0.34 |
148266 | ZNF569 | ATC5 | Human | Thyroid | ATC | 2.28e-36 | 6.89e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF569 | SNV | Missense_Mutation | c.872N>A | p.Ile291Asn | p.I291N | Q5MCW4 | protein_coding | deleterious(0) | possibly_damaging(0.813) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZNF569 | SNV | Missense_Mutation | c.1305N>C | p.Glu435Asp | p.E435D | Q5MCW4 | protein_coding | deleterious(0.02) | possibly_damaging(0.793) | TCGA-BH-A18K-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
ZNF569 | SNV | Missense_Mutation | c.785G>C | p.Arg262Thr | p.R262T | Q5MCW4 | protein_coding | deleterious(0.04) | benign(0.251) | TCGA-C8-A275-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ZNF569 | SNV | Missense_Mutation | c.1531A>G | p.Thr511Ala | p.T511A | Q5MCW4 | protein_coding | tolerated(0.74) | possibly_damaging(0.887) | TCGA-E9-A22G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
ZNF569 | SNV | Missense_Mutation | novel | c.1576N>A | p.Glu526Lys | p.E526K | Q5MCW4 | protein_coding | tolerated(0.2) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZNF569 | SNV | Missense_Mutation | novel | c.577N>C | p.Lys193Gln | p.K193Q | Q5MCW4 | protein_coding | tolerated(0.08) | benign(0.011) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZNF569 | SNV | Missense_Mutation | novel | c.14N>G | p.Gln5Arg | p.Q5R | Q5MCW4 | protein_coding | tolerated(0.07) | benign(0.055) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZNF569 | SNV | Missense_Mutation | c.1625N>C | p.Arg542Thr | p.R542T | Q5MCW4 | protein_coding | deleterious(0.02) | possibly_damaging(0.901) | TCGA-C5-A1BN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
ZNF569 | SNV | Missense_Mutation | novel | c.1175N>G | p.Ser392Cys | p.S392C | Q5MCW4 | protein_coding | deleterious(0.02) | probably_damaging(0.988) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
ZNF569 | SNV | Missense_Mutation | novel | c.1933C>G | p.Gln645Glu | p.Q645E | Q5MCW4 | protein_coding | tolerated(0.64) | benign(0.006) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |